GLUTAMIC ACID DECARBOXYLASE (GAD-65) ANTIBODY

The GLUTAMIC ACID DECARBOXYLASE (GAD-65) ANTIBODY test detects and quantifies autoantibodies directed against the GAD‑65 enzyme found in pancreatic beta cells. Performed on a serum sample using sensitive immunoassays, it identifies immune-mediated beta cell damage that is characteristic of type 1 diabetes and latent autoimmune diabetes in adults (LADA).

This at‑home test is suitable for individuals with new or atypical diabetes presentations, unstable glucose control, or a family history of type 1 diabetes. Samples are processed by accredited UAE laboratories, producing actionable results (qualitative/quantitative) that help clinicians decide on early insulin therapy, monitoring strategies, and specialist referral in Dubai and across the UAE.

• GAD‑65 Antibody (GAD65 IgG)
• GAD‑65 Antibody Titre (U/mL)
• Result — Positive / Negative
• Reference Range / Cut‑off Value
• Sample Type — Serum

• New‑onset diabetes in children or young adults
• Adult‑onset diabetes with lean phenotype or rapid insulin need (suspect LADA)
• Unexplained unstable glucose control or recurrent ketoacidosis
• First‑degree relatives of individuals with type 1 diabetes
• Prior to major treatment changes for diagnostic clarification

• Early detection of autoimmune diabetes risk and progression
• Helps differentiate autoimmune (type 1/LADA) from type 2 diabetes
• Guides personalised treatment decisions, including timely insulin initiation
• Convenient at‑home collection with testing in accredited UAE labs
• Fast, actionable results to support specialist referral and care planning

• At‑home venous blood collection by a trained phlebotomist
• No fasting required for GAD‑65 antibody testing
• Inform the team about recent immunotherapy or IVIG, which may affect results
• Provide valid Emirates ID and a summary of relevant medical history/medications